TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01263080

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirtazapine
Description: mirtazapine 30mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirtazapine
Description: mirtazapine 30mg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: folic acid placebo
Description: folic acid placebo 1 tablet QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folic acid placebo
Description: folic acid placebo 1 tablet QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mirtazapine placebo
Description: mirtazapine placebo 1 tablet QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mirtazapine placebo
Description: mirtazapine placebo 1 tablet QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folic acid
Description: folic acid 0.4mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: folic acid
Description: folic acid 0.4mg QD
Study: NCT02183662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 224436
Study: NCT00153062

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aggrenox placebo
Description: placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: 75 mg clopidogrel
Study: NCT02183662

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to BI 224436
Study: NCT03525236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tasting of flavours
Description: * Each patient will taste 5 products, in sequential-monadic test, randomized, one by one.~* Patients will take few sips of each study product, ideally in isolation (avoid influence of other patients)~* For each product tasted the subjects will be asked to answer a questionnaire including 1 question on the palatability of the product using a 10-point hedonic scale and a more detailed organoleptic evaluation of the product.~* Between product tastings, participants will have a 10 minutes break to rinse their mouth and fill in a questionnaire assessing sensory changes
Study: NCT00153062

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Clopidogrel
Description: 75 mg clopidogrel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Micardis placebo
Description: placebo
Study: NCT03760094

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Colour Doppler
Description: evaluation of lymph nodes by Doppler
Study: NCT03711513

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: All conditions start with a psycho-education session (PE). Subsequently, participants in condition A follow four exposure sessions (EX). Participants in condition B follow two cognitive restructuring (CR) followed by two exposure sessions. Participants in condition C follow two relaxation exercises sessions (RE) followed by two exposure sessions. All sessions will take place at their school in a group of five to eight adolescents (week 9,10,11,12,13,14). The sessions will be provided by a psychologist who receives training and supervision by a certified CBT therapist. The psychologist is assisted by a master student in psychology.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: All conditions start with a psycho-education session (PE). Subsequently, participants in condition A follow four exposure sessions (EX). Participants in condition B follow two cognitive restructuring (CR) followed by two exposure sessions. Participants in condition C follow two relaxation exercises sessions (RE) followed by two exposure sessions. All sessions will take place at their school in a group of five to eight adolescents (week 9,10,11,12,13,14). The sessions will be provided by a psychologist who receives training and supervision by a certified CBT therapist. The psychologist is assisted by a master student in psychology.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: All conditions start with a psycho-education session (PE). Subsequently, participants in condition A follow four exposure sessions (EX). Participants in condition B follow two cognitive restructuring (CR) followed by two exposure sessions. Participants in condition C follow two relaxation exercises sessions (RE) followed by two exposure sessions. All sessions will take place at their school in a group of five to eight adolescents (week 9,10,11,12,13,14). The sessions will be provided by a psychologist who receives training and supervision by a certified CBT therapist. The psychologist is assisted by a master student in psychology.
Study: NCT03563014

Intervention type: DRUG
Intervention: Radium-223 (Xofigo, Bay88-8223)
Description: Follow the physician's prescription in routine clinical practice.
Study: NCT01915810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete SCwPA intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete SCwPA intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Receive nicotine patch

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine Patch
Description: Receive nicotine patch

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine Patch
Description: Receive nicotine patch

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Receive smoking cessation counseling

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation Counseling
Description: Receive smoking cessation counseling
Study: NCT00153062

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Micardis placebo
Description: placebo
Study: NCT00679393

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Open reduction internal fixation
Description: Open reduction internal fixation surgery of severely comminuted calcaneal fracture (Sanders IV).

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Fusion
Description: Primary subtalar fusion of severely comminuted calcaneal fracture (Sanders IV)
Study: NCT04249154

Intervention type: DRUG
Group type: OTHER
Intervention: Eligard
Description: Eligard dose of 22.5mg given, 50Gy in 20 treatments of radiation therapy to start 12 weeks after first injection concurrent with second injection of Eligard
Study: NCT01206543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intraoperative imaging using 1.5T MRI
Description: Intraoperative imaging and determination of degree of resection / complete tumor removal
Study: NCT01304238

Intervention type: DRUG
Intervention: lepirudin
Description: lepirudin

Intervention type: DRUG
Intervention: danaparoid
Description: danaparoid

Intervention type: DRUG
Intervention: argatroban
Description: argatroban

Intervention type: DRUG
Intervention: fondaparinux
Description: fondaparinux
Study: NCT02470156

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Intensity Arm (Intervention)
Description: The high intensity intervention involves monthly wellness coaching, personalized goal setting, and progress tracking in addition to monthly group activities and social support.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Intensity Arm (Comparison)
Description: The low intensity intervention involves wellness coaching, personalized goal setting, and progress tracking at baseline, 4 months, 8 months, and 12 months.
Study: NCT04345757

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured exercise
Description: The exercise program will be designed by a physical therapist (Ms. Patricia Ladis) who specializes in postnatal rehabilitation and will be supervised by sports medicine physicians from the Hospital For Special Surgery (HSS). The structured program will include approximately 10 minutes of core muscle group exercises. They will begin this program 2 weeks after their cesarean section. The study group will perform these exercises 5 times per week.
Study: NCT02139293

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrimeStim
Description: Intermittent auricular vagus nerve stimulation at different ear points
Study: NCT02725346

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acromioplasty with planning

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acromioplasty without planning
Study: NCT03566446

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CALRLong36 peptide
Description: 200 ug CALRLong36 peptide in water mixed with 500ul montanide
Study: NCT01893294

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Description: Given IT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiation therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT04369716

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole oranges
Description: Navel oranges (227 g total)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Apples
Description: Red Delicious apple with skin (230 g)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Orange juice + orange pomace
Description: Orange Juice (149 g) + orange pomace (100g) \[40% pomace by weight\]

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Apple juice + apple pomace
Description: Apple Juice (129 g) + apple pomace (106 g) \[45% pomace by weight\]

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orange juice
Description: Orange Juice (250 g)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Apple juice
Description: Apple Juice (235 g)
Study: NCT02594761

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hercules
Description: Powder Concentrate for Intravenous Infusion, 150 mg/vial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin EU
Description: Powder for Concentrate for Solution for Infusion, 150 mg/vial

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Herceptin US
Description: Intravenous Infusion, 440 mg/vial
Study: NCT04200976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele-CABA
Description: Tele-CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of Tele-CABA focus on learning about TBI and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.~The Tele-CABA intervention will be delivered over 10 weekly, 60-minute telephone sessions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participants in the UC group will continue to receive their regular medical, psychiatric, and psychotherapeutic care.
Study: NCT03429231

Intervention type: DIETARY_SUPPLEMENT
Intervention: Coenzima Q - QubiquinolCoenzyme Q - Qubiquinol
Description: Patients in the active group will take one tablet a day orally
Study: NCT04033185

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: virtual reality, robot assisted gait training
Description: study group: 15 sessions virtual reality, robot assisted gait training

Intervention type: OTHER
Group type: OTHER
Intervention: conventional treatment
Description: study group: 15 sessions conventional treatment control group: 30 sessions conventional treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional treatment
Description: study group: 15 sessions conventional treatment control group: 30 sessions conventional treatment
Study: NCT01786473

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testogel 1%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02608593

Intervention type: PROCEDURE
Intervention: Strattice
Description: Implant based reconstruction with strattice cover of part or all of implant
Study: NCT02977585

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 10 cmH2O peep
Description: positive end expiratory pressure
Study: NCT00798915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intravenous infusion of 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic Polypeptide (GIP)
Description: Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic Polypeptide (GIP)
Description: Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic Polypeptide (GIP)
Description: Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenin-25
Description: Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenin-25
Description: Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenin-25
Description: Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Description: Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
Study: NCT01915810

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tobacco Cessation Counseling
Description: Receive smoking cessation counseling
Study: NCT03923166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Description: 400mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: capecitabine 500mg tid
Study: NCT03216525

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alvimopan
Description: To determine if Alvimopan during radical cystectomy with urinary diversion results in faster return of bowel function.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: To determine if placebo during radical cystectomy with urinary diversion results in faster return of bowel function.
Study: NCT00798915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Description: Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glucose-dependent Insulinotropic Polypeptide plus Xenin-25
Description: Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
Study: NCT02819011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MBB AFO
Description: Subjects will be provided with a pair of New Balance 813 shoes plus a custom made MBB AFO

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Subjects will be provided with a pair of New Balance 813 shoes
Study: NCT01962350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Transcranial Magnetic Stimulation
Description: H1-Coil deep brain rTMS at cortex prefrontal.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Transcranial Magnetic Stimulation
Description: H1-Coil deep brain rTMS at cortex prefrontal.
Study: NCT02504593

Intervention type: DEVICE
Group type: OTHER
Intervention: mHealth platform employing Fionet Deki Readers to ensure quality of community-based malaria diagnosis
Description: The investigators propose to implement a new mobile interface that automatically reads and troubleshoots malaria rapid diagnostic test (RDT) cassettes. This device, called a Deki reader (DR), will allow the investigators to establish an extensive quality assurance program of malaria diagnosis performed by trained community health volunteers (CHVs). To ensure high-quality diagnosis by CHVs, the study team will deploy 10 Fionet DRs and rotate them amongst 200 CHVs who have been trained to do RDTs. In the first phase, each CHV will use the device for 10 successive clients presenting themselves for malaria diagnosis to the CHV, and then the device will be rotated to another CHV.
Study: NCT01748734

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: counseling intervention
Description: Undergo cognitive behavioral therapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral intervention
Description: Undergo cognitive behavioral therapy
Study: NCT03964831

Intervention type: DEVICE
Group type: OTHER
Intervention: P200TxE
Description: The P200TxE ophthalmoscope provides widefield scanning laser ophthalmascope (SLO) fundus imaging.

Intervention type: DEVICE
Group type: OTHER
Intervention: P200DTx
Description: The P200DTx ophthalmoscope provides widefield scanning laser ophthalmascope (SLO) fundus imaging.
Study: NCT00672893

Intervention type: OTHER
Intervention: Vibration Response Imaging
Description: 12 seconds of recording lung sounds
Study: NCT00736021

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Escitalopram
Description: Up to 40 mg oral dose in 10 or 20 mg tablets taken twice daily
Study: NCT01748747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montanide ISA 51 VG
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1 antigen
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1 antigen
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MART-1 antigen
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gag:267-274 peptide vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gag:267-274 peptide vaccine
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: resiquimod
Description: Applied topically
Study: NCT00247663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Study: NCT01724346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Next-line ibrutinib
Description: Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily
Study: NCT03208829

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation exercises
Description: Patients in group 1 will participate in a physical exercise protocol supervised by a physiotherapist. The sessions will focus on the rehabilitation of muscle strength and the exercises will be performed with increased external load.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Postoperative guidance
Description: Group 2 will receive only guidelines regarding postoperative care.
Study: NCT02952508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopofosine I 131 single dose
Description: Radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopofosine I 131 single dose
Description: Radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopofosine I 131 single dose
Description: Radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopofosine I 131 multiple dose
Description: Radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopofosine I 131 multiple dose
Description: Radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopofosine I 131 multiple dose
Description: Radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopofosine I 131 fractionated dose
Description: Radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopofosine I 131 fractionated dose
Description: Radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopofosine I 131 fractionated dose
Description: Radiopharmaceutical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iopofosine I 131 fractionated dose
Description: Radiopharmaceutical
Study: NCT03545555

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kale Preparation Kale Powder
Description: Effect of kale preparation kale powder on lipid status

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kale Preparation Kale Extract
Description: Effect of kale preparation kale extract on lipid status

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Kale Preparation Flavonoid Extract
Description: Effect of kale preparation flavonoid extract on lipid status

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Effect of placebo on lipid status